Kyowa Kirin has announced a significant advancement in the treatment landscape for X-linked hypophosphatemia (XLH) in adult patients, following the…
Read More
Isomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and Development
AI drug design and development firm Isomorphic Labs has successfully closed a significant $2.1 billion Series B funding round, marking…
Read More
GSK Secures Promising Metabolic Oligonucleotide Therapy Rights from SiranBio in Up to $1 Billion Deal
In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Citius Oncology Secures Up to $36.5 Million in Debt and Equity Financing to Fuel Lymphir Commercialization
Citius Oncology has successfully secured a significant financial infusion, totaling up to $36.5 million, through a strategic combination of debt…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
Pfizer Secures Extended Market Exclusivity for Vyndamax, Delaying Generic Competition Until 2031
Pfizer has successfully negotiated settlements with three drug manufacturers, Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, preventing the immediate launch of…
Read More
Novartis Secures Dual Regulatory Milestones: European Approval for Rhapsido and WHO Prequalification for Coartem Baby
Novartis has achieved significant regulatory successes on two fronts, with its oral therapy Rhapsido (remibrutinib) receiving marketing authorisation from the…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Idvynso Secures FDA Approval, Charting a New Course in HIV Treatment While Biktarvy Maintains Market Dominance
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
